NGS expansion CD Genomics has actively expanded into Next-Generation Sequencing and RNA-focused platforms, signaling a growing capability to support clients with comprehensive sequencing services that can address large-scale projects and diverse research needs.

Diversified offerings With services spanning sequencing, microarray analysis, library construction, genotyping, and targeted RNA sequencing, there are multiple entry points for upsell opportunities across academic, pharmaceutical, and government accounts.

Global reach Active client base in over 50 countries suggests potential for expanding collaborations in new regions or deepening engagements with existing international partners, including cross-border project consulting and multi-site studies.

Advanced tech Recent launches of Total RNA Sequencing, Dual RNA-seq, OxBS-seq, Ribosome Profiling, and full-length Amplicon sequencing demonstrate cutting-edge capabilities that can be positioned to win data-intensive or specialized projects from competitive institutions.

Financial visibility Revenue in the lower to mid multi-million range indicates a need for scalable, service-driven engagements with longer project lifecycles, enabling consistent recurring revenue through retainer-based or long-term collaboration models.